Tobias Walbert

Neurology

2800 W Grand Blvd
Detroit, MI 48202

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 90 publications

Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.

Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.

Journal: medRxiv : the preprint server for health sciences

Published: July 03, 2026

Single-nucleus multiomics unveils malignant cellular states, regulatory architectures and microenvironmental reorganization across the G-CIMP epigenomic transition in IDH-mutant glioma.

Single-nucleus multiomics unveils malignant cellular states, regulatory architectures and microenvironmental reorganization across the G-CIMP epigenomic transition in IDH-mutant glioma.

Journal: bioRxiv : the preprint server for biology

Published: June 22, 2026

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 07, 2026

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 14, 2026

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).

Journal: AJNR. American journal of neuroradiology

Published: February 19, 2026

Temporalis Muscle Thickness as a Prognostic Factor for 30-Day, 90-Day, and Overall Mortality in Newly Diagnosed Glioblastoma.

Temporalis Muscle Thickness as a Prognostic Factor for 30-Day, 90-Day, and Overall Mortality in Newly Diagnosed Glioblastoma.

Journal: Cureus

Published: February 18, 2026

Palliative Care in Neuro-oncology.

Palliative Care in Neuro-oncology.

Journal: Continuum (Minneapolis, Minn.)

Published: December 02, 2025

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 01, 2025

Electronic assessment of health-related quality of life in glioblastoma patients using the EORTC-QLQ-C30/EORTC-BN20 and the PROMIS system in clinical practice.

Electronic assessment of health-related quality of life in glioblastoma patients using the EORTC-QLQ-C30/EORTC-BN20 and the PROMIS system in clinical practice.

Journal: Neuro-oncology advances

Published: October 13, 2025

Quality measurements in neuro-oncology: A critical look at glioblastoma indicators and the path forward.

Quality measurements in neuro-oncology: A critical look at glioblastoma indicators and the path forward.

Journal: Neuro-oncology practice

Published: October 13, 2025

Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium.

Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium.

Journal: Neuro-oncology

Published: August 30, 2025

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

Journal: Nature medicine

Published: August 29, 2025

Showing 1-12 of 90

Last Updated: 09/26/2026